PDCD1 and neoplasm: Blocking PD-1–PD-L1/PD-L2 interactions restores the cytotoxic function of antigen-experienced T cells, prevents exhaustion under chronic antigen exposure, and expands tumor-specific CD8+ T cell subsets (33–35).